-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) Tops Q1 EPS by 10c
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) PT Raised to $20 at BofA Securities
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) PT Raised to $15 at RBC Capital
-
-
-
-
-
-
-
Goldman: ' the inability to fully screen at-risk patients could be a factor in the competitive dynamics in ATTR'
-
-
-
-
-
-
-
Wolfe Research Downgrades Intellia Therapeutics (NTLA) to Peerperform
-
-
-
-
-
-
-
Form SCHEDULE 13G/A Intellia Therapeutics, Filed by: ARK Investment Management LLC
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) PT Lowered to $29 at Citizens on Nex-Z (ATTR) Risk
-
434,045 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

